CA3198414A1 - Method for treating ox40 related disease - Google Patents

Method for treating ox40 related disease

Info

Publication number
CA3198414A1
CA3198414A1 CA3198414A CA3198414A CA3198414A1 CA 3198414 A1 CA3198414 A1 CA 3198414A1 CA 3198414 A CA3198414 A CA 3198414A CA 3198414 A CA3198414 A CA 3198414A CA 3198414 A1 CA3198414 A1 CA 3198414A1
Authority
CA
Canada
Prior art keywords
weeks
week
khk4083
antibody
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3198414A
Other languages
English (en)
French (fr)
Inventor
Mitsuo Sato
Yoshinori Nagata
Kenji Ootaki
Nobuyuki Imai
Munetake Shimabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of CA3198414A1 publication Critical patent/CA3198414A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3198414A 2020-10-09 2021-10-08 Method for treating ox40 related disease Pending CA3198414A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063089809P 2020-10-09 2020-10-09
US63/089,809 2020-10-09
US202063116365P 2020-11-20 2020-11-20
US63/116,365 2020-11-20
US202163233592P 2021-08-16 2021-08-16
US63/233,592 2021-08-16
PCT/JP2021/037481 WO2022075476A1 (en) 2020-10-09 2021-10-08 Method for treating ox40 related disease

Publications (1)

Publication Number Publication Date
CA3198414A1 true CA3198414A1 (en) 2022-04-14

Family

ID=81126528

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3198414A Pending CA3198414A1 (en) 2020-10-09 2021-10-08 Method for treating ox40 related disease

Country Status (11)

Country Link
US (1) US20230383001A1 (https=)
EP (1) EP4225371A4 (https=)
JP (1) JP2023545084A (https=)
KR (1) KR20230084166A (https=)
CN (1) CN116437955A (https=)
AU (1) AU2021358274A1 (https=)
CA (1) CA3198414A1 (https=)
IL (1) IL301935A (https=)
MX (1) MX2023004113A (https=)
TW (1) TW202222343A (https=)
WO (1) WO2022075476A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326123A (en) * 2023-07-25 2026-03-01 Inmagene Pte Ltd Treatment methods for alopecia areata and atopic dermatitis
WO2025244002A1 (ja) * 2024-05-21 2025-11-27 国立大学法人京都大学 ベンダムスチンによるｔ細胞の減少を抑制するために使用されるｔ細胞減少抑制剤
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
PT3528838T (pt) * 2016-09-23 2023-09-04 Hoffmann La Roche Utilizações de antagonistas de il-13 para tratamento de dermatite atópica
WO2019229155A1 (en) * 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders

Also Published As

Publication number Publication date
AU2021358274A9 (en) 2024-05-30
TW202222343A (zh) 2022-06-16
IL301935A (en) 2023-06-01
EP4225371A1 (en) 2023-08-16
AU2021358274A1 (en) 2023-05-25
JP2023545084A (ja) 2023-10-26
KR20230084166A (ko) 2023-06-12
CN116437955A (zh) 2023-07-14
WO2022075476A1 (en) 2022-04-14
EP4225371A4 (en) 2024-11-20
MX2023004113A (es) 2023-06-29
US20230383001A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
TWI852712B (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
CA3198414A1 (en) Method for treating ox40 related disease
US20220169705A1 (en) Topical application for an anti-hsv antibody
CN114173816A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
US20100055098A1 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
US20230374124A1 (en) Compositions for treatment alopecia areata, biomarkers for treatment success and, methods of use thereof
WO2013024155A1 (en) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
US20250059290A1 (en) Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseases
TW202330614A (zh) 抗ｔｒｅｍ２抗體及其用途
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
TW201929899A (zh) 治療IgE介導的過敏性疾病
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
TWI790457B (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
TW202515895A (zh) 靶向ｂ型肝炎病毒（ｈｂｖ）之重組多株蛋白及其使用方法
KR20250135238A (ko) 면역 매개 괴사성 근병증의 치료 및 예방을 위한 항-cd19 결합제
US20240228644A1 (en) Treatment for systemic lupus erythematosus using anti-baffr antibodies
EA052089B1 (ru) Антитела для лечения хронического заболевания "трансплантат против хозяина"

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250902

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250902

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251002

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251002

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251204

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251204

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251204

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251209